Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Kraig Biocraft Laboratories (KBLB) EBITDA (2016 - 2022)

Kraig Biocraft Laboratories (KBLB) has disclosed EBITDA for 10 consecutive years, with -$946847.0 as the latest value for Q4 2022.

  • Quarterly EBITDA fell 83.2% to -$946847.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$3.3 million through Dec 2022, down 21.07% year-over-year, with the annual reading at -$760904.0 for FY2025, 75.25% up from the prior year.
  • EBITDA hit -$946847.0 in Q4 2022 for Kraig Biocraft Laboratories, down from -$810356.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$147948.0 in Q3 2018 to a low of -$1.1 million in Q3 2019.
  • Historically, EBITDA has averaged -$590977.3 across 4 years, with a median of -$545711.0 in 2022.
  • Biggest five-year swings in EBITDA: soared 87.42% in 2018 and later plummeted 614.34% in 2019.
  • Year by year, EBITDA stood at -$432515.0 in 2018, then tumbled by 144.35% to -$1.1 million in 2019, then soared by 51.1% to -$516829.0 in 2021, then crashed by 83.2% to -$946847.0 in 2022.
  • Business Quant data shows EBITDA for KBLB at -$946847.0 in Q4 2022, -$810356.0 in Q3 2022, and -$1.0 million in Q2 2022.